Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730148 | 0.87 | CACNA1G (0.35) | CACNA1GCACNA1BCACNA1CPOLBL3MBTL1 | |
| SCHEMBL19730146 | 0.87 | TDP1 (0.33) | CACNA1GCACNA1BCACNA1CAAK1POLB | |
| SCHEMBL19730159 | 0.86 | PNP (0.35) | CACNA1GCACNA1BCACNA1CPOLBL3MBTL1 | |
| SCHEMBL13667386 | 0.79 | EGLN1 (0.39) | AAK1POLBL3MBTL1NPSR1TDP1 | |
| SCHEMBL19730149 | 0.78 | L3MBTL1 (0.36) | POLBMEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL19730138 | 0.75 | TDP1 (0.33) | AAK1POLBMEN1KMT2AL3MBTL1 | |
| SCHEMBL26068373 | 0.75 | MEN1 (0.34) | POLBMEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL19730139 | 0.74 | L3MBTL1 (0.33) | CACNA1GCACNA1BCACNA1CPOLBMEN1 | |
| SCHEMBL19730137 | 0.74 | L3MBTL1 (0.33) | POLBMEN1KMT2AL3MBTL1NPSR1 | |
| SCHEMBL29593049 | 0.74 | L3MBTL1 (0.33) | CACNA1GCACNA1BCACNA1CPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | CACNA1G 1684/4885CACNA1B 1064/4885CACNA1C 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.